One thing that all sides agree on in the tripartite fight over control of Amylin's board of directors is that the launch of exenatide once weekly, the long-acting version of its diabetes drug Byetta, ...

Shares of both Eli Lilly and Amylin Pharmaceuticals rose Tuesday after the partners on diabetes drug Byetta told physicians they could begin writing new Byetta prescriptions for diabetes patients. Two ...

SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced ...

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

SAN DIEGO and INDIANAPOLIS, Oct. 19, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration ...

BUFFALO, N.Y. -- Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at ...

Ever wonder why acquisition-minded CEO John Lechleiter has been cool to the idea of Eli Lilly and Co. buying Amylin Pharmaceuticals Inc., Lilly’s partner on the diabetes medicine Byetta? One reason ...

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes in adults. This drug can interact with other medications and some supplements. For example, Byetta can interact with ...

The FDA gives Amylin and Alkermes a smack down. The companies announced bad news yesterday. The FDA wouldn't let Amylin use its in vitro-in vivo correlation studies to prove that the extended-release ...

The fourth quarter was worse than expected for Amylin Pharmaceuticals , whose diabetes franchise Byetta has seen better days. Yet, the company is hoping a new version of the drug will be the medicine ...